This pooled analysis of the phase IIb AMP studies observed that in vitro susceptibility of circulating HIV-1 isolates to the broadly neutralizing antibody, VRC01, predicts prevention efficacy in MSM, transgender persons, and cisgender women.
TAF implants provided complete protection against vaginal SHIV infection, but high rates of dermatologic toxicity were observed at implant sites.
Monthly cabotegravir injections were associated with an 89% lower risk of HIV infection vs daily oral TDF/FTC; both strategies were generally safe and well tolerated, with no discontinuations for injection-site reactions.
Interim analysis showed that islatravir administered once monthly achieved the prespecified pharmacokinetic threshold for predicted HIV pre-exposure prophylaxis efficacy.
In this small pharmacokinetic study, tissue CAB concentrations longitudinally mirrored plasma CAB concentrations with no drug-related ISRs leading to participant withdrawal.
Both tenofovir and levonorgestrel met concentration targets in a 90-day trial assessing the TFV/LNG vaginal ring vs placebo, supporting further study of the TFV/LNG ring for HIV prevention.
Across 2 independent surveys of US MSM, 10% to 18% of participants indicated a preference for on-demand vs daily PrEP dosing yet only 1% to 3% of current PrEP recipients were using on-demand dosing.
In this observational, single-center cohort study, integration of PrEP services at the first antenatal care visit was associated with 91% of women initiating PrEP.
Among 622 STI screens among adolescent girls and young women, 34% returned positive, most commonly for chlamydia. Of those diagnosed with an STI, 65% received treatment.
The average for self-reported days of PrEP use declined from 74% before COVID-19 restrictions to 58% after in this Amsterdam demonstration project.